» Articles » PMID: 19331659

A Signature-based Method for Indexing Cell Cycle Phase Distribution from Microarray Profiles

Overview
Journal BMC Genomics
Publisher Biomed Central
Specialty Genetics
Date 2009 Apr 1
PMID 19331659
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The cell cycle machinery interprets oncogenic signals and reflects the biology of cancers. To date, various methods for cell cycle phase estimation such as mitotic index, S phase fraction, and immunohistochemistry have provided valuable information on cancers (e.g. proliferation rate). However, those methods rely on one or few measurements and the scope of the information is limited. There is a need for more systematic cell cycle analysis methods.

Results: We developed a signature-based method for indexing cell cycle phase distribution from microarray profiles under consideration of cycling and non-cycling cells. A cell cycle signature masterset, composed of genes which express preferentially in cycling cells and in a cell cycle-regulated manner, was created to index the proportion of cycling cells in the sample. Cell cycle signature subsets, composed of genes whose expressions peak at specific stages of the cell cycle, were also created to index the proportion of cells in the corresponding stages. The method was validated using cell cycle datasets and quiescence-induced cell datasets. Analyses of a mouse tumor model dataset and human breast cancer datasets revealed variations in the proportion of cycling cells. When the influence of non-cycling cells was taken into account, "buried" cell cycle phase distributions were depicted that were oncogenic-event specific in the mouse tumor model dataset and were associated with patients' prognosis in the human breast cancer datasets.

Conclusion: The signature-based cell cycle analysis method presented in this report, would potentially be of value for cancer characterization and diagnostics.

Citing Articles

A signature of enhanced proliferation associated with response and survival to anti-PD-L1 therapy in early-stage non-small cell lung cancer.

Altorki N, Bhinder B, Borczuk A, Elemento O, Mittal V, McGraw T Cell Rep Med. 2024; 5(3):101438.

PMID: 38401548 PMC: 10982989. DOI: 10.1016/j.xcrm.2024.101438.


Rapid assessment of the immunogenicity potential of engineered antibody therapeutics through detection of CD4 T cell interleukin-2 secretion.

Arata Y, Motoyama S, Yano M, Ikuno T, Ito S, Matsushita T MAbs. 2023; 15(1):2253570.

PMID: 37682072 PMC: 10494738. DOI: 10.1080/19420862.2023.2253570.


Isosorbide Fatty Acid Diesters Have Synergistic Anti-Inflammatory Effects in Cytokine-Induced Tissue Culture Models of Atopic Dermatitis.

Swindell W, Bojanowski K, Chaudhuri R Int J Mol Sci. 2022; 23(22).

PMID: 36430783 PMC: 9696169. DOI: 10.3390/ijms232214307.


BET Inhibitors Target the SCLC-N Subtype of Small-Cell Lung Cancer by Blocking NEUROD1 Transactivation.

Chen H, Gesumaria L, Park Y, Oliver T, Singer D, Ge K Mol Cancer Res. 2022; 21(2):91-101.

PMID: 36378541 PMC: 9898120. DOI: 10.1158/1541-7786.MCR-22-0594.


The Cancer SENESCopedia: A delineation of cancer cell senescence.

Jochems F, Thijssen B, De Conti G, Jansen R, Pogacar Z, Groot K Cell Rep. 2021; 36(4):109441.

PMID: 34320349 PMC: 8333195. DOI: 10.1016/j.celrep.2021.109441.


References
1.
Baker F, Sanger L, Rodgers R, Jabboury K, Mangini O . Cell proliferation kinetics of normal and tumour tissue in vitro: quiescent reproductive cells and the cycling reproductive fraction. Cell Prolif. 1995; 28(1):1-15. DOI: 10.1111/j.1365-2184.1995.tb00035.x. View

2.
Sun H, Lesche R, Li D, Liliental J, Zhang H, Gao J . PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci U S A. 1999; 96(11):6199-204. PMC: 26859. DOI: 10.1073/pnas.96.11.6199. View

3.
Gonzalez M, Tachibana K, Chin S, Callagy G, Madine M, Vowler S . Geminin predicts adverse clinical outcome in breast cancer by reflecting cell-cycle progression. J Pathol. 2004; 204(2):121-30. DOI: 10.1002/path.1625. View

4.
Lemoine F, Marriott S . Accelerated G(1) phase progression induced by the human T cell leukemia virus type I (HTLV-I) Tax oncoprotein. J Biol Chem. 2001; 276(34):31851-7. DOI: 10.1074/jbc.M105195200. View

5.
Williams G, Stoeber K . Cell cycle markers in clinical oncology. Curr Opin Cell Biol. 2007; 19(6):672-9. DOI: 10.1016/j.ceb.2007.10.005. View